For International Women’s Day, Adiso celebrates our incredible female colleagues and the achievements of women globally. We’re proud to support this year’s theme to embrace equity as we continue to foster a diverse and compassionate company culture centered on helping patients.

On Employee Appreciation Day, we’d like to give thanks to our talented Adiso team. Every day, we are grateful for your commitment to upholding our mission to develop novel therapies for inflammatory disease.

Adiso is proud to participate in the 2023 Biocom California Global Life Science Partnering and Investor Conference, where Adiso CEO Scott Megaffin will present the strong progress across our differentiated pipeline of novel therapeutics for inflammatory disease.

In honor of International Day of Women and Girls in Science, we’d like to spotlight our incredible CBO Jennifer Locke for her dedication to uplifting women leaders and helping patients in need. Read what she has to say about her career in the biotech pharma industry.

Thank you to the organizers of the Banff Inflammation Workshop for the opportunity to present data on Adiso’s ADS032 and ADS051, two small molecule inhibitors that locally inhibit in a multimodal approach inflammasomes and neutrophils in a highly differentiated way. Adiso collaborated with The University of Edinburgh. Anu Fernando highlighted the instrumental role of ADS032 and ADS051 in the modulation of inflammation.

Adiso wishes you a safe and happy holiday season. With the new year approaching, we’re taking time to reflect on our accomplishments in 2022 and give thanks to all who have made our success possible. We hope everyone has a joyful time with friends & family happy holidays.

Adiso is excited to present at Biotech Showcase and the J.P. Morgan Healthcare Conference next month. We look forward to seeing everyone in person and invite you to connect with us in San Francisco.  

Come join us at the East-West Biopharma Summit. Our CEO Scott Megaffin will participate in a panel discussion and present on our innovative, multi-modal pipeline for inflammatory disease. See you there!

 

Adiso is excited to attend Demy-Colton’s BioFuture 2022, where our CEO Scott Megaffin will present our differentiated approach to inflammatory disease and provide an overview of the Adiso development programs. Let’s connect!

We are Hiring! Adiso Therapeutics has partnered with Mix Talent. Come Join our growing team and help us on our mission to improve the lives of patients and their families through the advancement of our innovative pipeline of therapeutics all with novel mechanisms of action. Learn more and apply for these opportunities here: https://bit.ly/3CV8nFu; https://bit.ly/3TFjKYX

 

Looking forward to presenting data at ACG2022 from our preclinical study of ADS024 highlighting its potential to improve disease activity index and reduce measures of inflammation in mice with induced colitis.

Adiso is providing a corporate update and overview of the Adiso development programs for inflammatory disease of high unmet medical need at Sofinnova Partners Japan Biopharma Partnering Conference.

Adiso is honored to attend Solebury Strategic Communications Fall Private Company Showcase, where CEO Scott Megaffin will present our unique approach to inflammatory disease and give a progress update across our pipeline. 

We are excited for our Head of Translational Science Ashley Mansell to present preclinical data on Adiso’s ADS032, a novel candidate blocking two types of inflammasomes NLRP1 and NLRP3 with the ability to reduce LPS-induced systemic inflammation, and silica- and IAV-mediated pulmonary disease. Click here to View the poster.

Our Sr. Director of Research Susan Acton will be presenting data at The International Congress of Parkinson’s Disease and Movement Disorders from our preclinical study of ADS024 highlighting its potential for preventing dopamine loss and improving motor movement in Parkinson’s Disease.

Proudly announcing an ADS032 poster presentation at European Respiratory Society! We’ll be describing an ex-vivo study done in collaboration with The University of Edinburgh of ADS032, a dual inflammasome inhibitor with a highly differentiated anti inflammatory approach and potential use across a range of diseases.

It’s with great pleasure we announce that cohorts 1 & 2 are fully enrolled in our Phase 1b study of ADS051 for the treatment of moderate to severe ulcerative colitis.

At the International Narcotics Research Conference (INRC) we enjoyed presenting the outstanding work of our Adiso team, a poster highlighting the impact of our SS-LBP, ADS012, on the gut-brain axis.

We had a blast volunteering at Food For Free. Not only was it an opportunity to help food-insecure residents in the Greater Boston Area it was also a genuinely fun team bonding experience. We packed over 360 Boxes of fresh groceries, at 25lbs each. 

To find out more about Food For Free visit Volunteer – FoodForFree.org.

      

Our incredible CTO Bharat Dixit is presenting today on our single strain live biotherapeutic platform at the Microbiome Movement Drug Development Summit at 5pm EST.

We’ll be attending this year’s BIO International Convention! On June 13 at 1:15 p.m. PDT, we will be giving a company presentation on our innovative pipeline of small molecules and single strain live biotherapeutic products to treat inflammatory diseases.

Want to learn more about our lead asset, ADS024, and its ability to degrade C.difficile toxins? See our manuscript published in Scientific Reports describing how ADS024 directly kills Clostridiodes difficile and degrades its toxins: Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities | Scientific Reports (nature.com) or as a PDF here.

For world IBD day 2022, we are joining the global community in recognizing patients suffering from ulcerative colitis. At Adiso, we are committed to advancing therapies for inflammatory diseases. Learn more about World IBD Day here: 19 May, World IBD Day – Crohn’s disease and ulcerative colitis

We are looking forward to hearing our Chief Technology Officer, Bharat Dixit, speak at the SAPA-NE Bimonthly Seminar on a topic he knows well – developing microbes as medicines. Register here for his talk on the microbiome: SAPA-NE 2022 Bimonthly Workshop- Technology Trends | SAPA-NE (sapa-neweb.org)